Eric Easom - Feb 26, 2025 Form 4 Insider Report for AN2 Therapeutics, Inc. (ANTX)

Role
Chief Executive Officer, Director
Signature
/s/ Lucy Day, Attorney-in-Fact for Eric Easom
Stock symbol
ANTX
Transactions as of
Feb 26, 2025
Transactions value $
$0
Form type
4
Date filed
2/28/2025, 04:22 PM
Previous filing
Nov 18, 2024
Next filing
Jun 3, 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ANTX Common Stock Award $0 +145K +143.63% $0.00 246K Feb 26, 2025 Direct F1, F2
holding ANTX Common Stock 1.07M Feb 26, 2025 See Footnote F3
holding ANTX Common Stock 97.1K Feb 26, 2025 See Footnote F4
holding ANTX Common Stock 97.1K Feb 26, 2025 See Footnote F5

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ANTX Stock Option (right to buy) Award $0 +291K $0.00 291K Feb 26, 2025 Common Stock 291K $1.13 Direct F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents restricted stock units ("RSUs") which vest as follows: 1/4th of the shares vests annually over four years from January 1, 2025, subject to the Reporting Person's continuous service as of such date.
F2 Includes a balance of 99,000 RSUs which vest as follows: 1/4th of the shares vests annually over four years from January 1, 2024, subject to the Reporting Person's continuous service as of each such date.
F3 Consists of shares of Common Stock held by the Easom Living Trust dated August 21, 2019.
F4 Consists of shares of Common Stock held by the C. Easom Irrevocable Trust dated October 8, 2021.
F5 Consists of shares of Common Stock held by the Jude Easom Irrevocable Trust dated October 8, 2021.
F6 The shares subject to the option vest as follows: 1/48th of the shares vests monthly over four years from January 1, 2025, subject to the Reporting Person's continuous service as of such date.